Difference between revisions of "Talk:ELOC-mutated renal cell carcinoma"
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
cyclin D1, beta-catenin ??? | cyclin D1, beta-catenin ??? | ||
https://pubmed.ncbi.nlm.nih.gov/31748879/ | |||
cyclin D1 +ve subset of ccRCC has favourable prognosis | |||
https://pubmed.ncbi.nlm.nih.gov/35653922/ | |||
https:// | ==Antibodies== | ||
https://www.antibodies.com/products/primary-antibodies/tceb1-antibodies | |||
Latest revision as of 16:27, 6 March 2025
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931622/ cyclin D1, beta-catenin ???
https://pubmed.ncbi.nlm.nih.gov/31748879/ cyclin D1 +ve subset of ccRCC has favourable prognosis
https://pubmed.ncbi.nlm.nih.gov/35653922/
Antibodies
https://www.antibodies.com/products/primary-antibodies/tceb1-antibodies